Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alligator Bioscience

0.01 SEK-2.30 %19.11, 15.51
Less than 1K followers

ATORX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-2.30 %
-35.61 %
-58.29 %
-94.41 %
-96.29 %
-95.71 %
-99.87 %
-99.96 %
-100.00 %

Alligator Bioscience is a research-based biotechnology company. The company uses a patented technology to develop biological drug candidates in inflammation and cancer, and is active in the earlier part of the drug development chain. Alligator Bioscience has a global technology platform and is active in the protein pharmaceutical segment. The company was founded in 2001 and is headquartered in Lund.

Read more
Market cap
30.33M SEK
Turnover
63.37K SEK
Revenue
510K
EBIT %
-20,750.2 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27.11
2026

Extraordinary general meeting '26

11.2
2027

Annual report '26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release13.11.2026, 16.00

Nomination Committee of Alligator Bioscience proposes new board and reduced fees ahead of extraordinary general meeting on 27 November 2026

Alligator Bioscience
Regulatory press release03.11.2026, 15.00

Nomination Committee appointed in respect of AGM 2027 in Alligator Bioscience AB

Alligator Bioscience
Press release02.11.2026, 14.16

Redeye: Alligator Bioscience: Mitazalimab sold to Biossil

Alligator Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release31.10.2026, 08.15

Alligator Bioscience signs agreement to sell mitazalimab to Biossil

Alligator Bioscience
Regulatory press release30.10.2026, 09.00

Change in number of shares and votes in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release27.10.2026, 18.15

Notice of extraordinary general meeting in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release27.10.2026, 18.00

The Board of Directors of Alligator Bioscience proposes a reverse share split of ordinary shares

Alligator Bioscience
Press release23.10.2026, 14.21

Redeye: Alligator Bioscience (Q3 Review): Partnering Mitazalimab to Fund HLX22

Alligator Bioscience
Regulatory press release22.10.2026, 08.00

Alligator Bioscience AB reports financial results for the period 1 January – 30 September 2026 and provides a business update

Alligator Bioscience
Press release15.10.2026, 14.00

Invitation to Alligator Bioscience’s interim report call on 22 October 2026

Alligator Bioscience
Press release05.10.2026, 11.37

Redeye: Alligator Bioscience: CFO Johan Giléus to Take Over as CEO

Alligator Bioscience
Regulatory press release04.10.2026, 15.45

Alligator Bioscience appoints Johan Giléus as CEO – Søren Bregenholt to step down at year-end

Alligator Bioscience
Regulatory press release29.09.2026, 11.45

Alligator Bioscience carries out a directed issue of warrants to Fenja Capital in connection with the completed rights issue

Alligator Bioscience
Regulatory press release22.09.2026, 16.30

Alligator Bioscience announces final outcome in rights issue

Alligator Bioscience
Press release21.09.2026, 16.56

Redeye: Alligator Bioscience: 17% Preliminary Subscription Rate

Alligator Bioscience
Regulatory press release21.09.2026, 11.45

Alligator Bioscience announces preliminary outcome in rights issue

Alligator Bioscience
Regulatory press release31.08.2026, 14.15

Alligator Bioscience publishes prospectus in connection with rights issue

Alligator Bioscience
Press release28.08.2026, 11.15

Redeye: Alligator Bioscience (Q2 2026 Review): The HLX22 waiting game

Alligator Bioscience
Regulatory press release26.08.2026, 11.30

Bulletin from the extraordinary general meeting in Alligator Bioscience AB

Alligator Bioscience
Regulatory press release26.08.2026, 08.00

Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update

Alligator Bioscience